Related Experiment Videos
High-performance liquid chromatographic assay for the experimental anticancer agent oxantrazole
S K Frank1, D A Mathiesen, L R Whitfield
1Department of Oncology, Mayo Clinic and Foundation, Rochester, MN 55905.
Journal of Chromatography
|August 7, 1987
Summary
Oxantrazole, an anthracycline-like agent, was analyzed using a novel HPLC assay. Pharmacokinetic studies in dogs revealed rapid plasma elimination with a half-life under 45 minutes.
Area of Science:
- Pharmacology
- Analytical Chemistry
- Drug Development
Background:
- Oxantrazole is an anthrapyrazole analogue designed as an anthracycline-like agent.
- Potential for reduced cardiotoxicity compared to traditional anthracyclines.
Purpose of the Study:
- Develop and validate a reversed-phase high-performance liquid chromatographic (RP-HPLC) assay for oxantrazole.
- Determine the plasma pharmacokinetics of oxantrazole in beagle dogs.
Main Methods:
- Utilized a C2 column with a mobile phase of dimethylformamide-acetonitrile-ammonium acetate.
- Detection via ultraviolet absorbance at 514 nm.
- Quantification in plasma using C18 isolation columns and RP-HPLC.
Main Results:
- The assay demonstrated linearity (r² > 0.99) from 0.025-2.5 µg/ml with a limit of detection of 10 ng/ml.
- Oxantrazole exhibited instability in neutral and alkaline aqueous solutions.
- Rapid plasma elimination in beagle dogs with elimination half-lives < 45 minutes.
Conclusions:
- A validated HPLC assay enables the pharmacokinetic analysis of oxantrazole.
- Oxantrazole is rapidly eliminated from plasma, suggesting specific dosing strategies may be required.
- Further research into oxantrazole's stability and therapeutic potential is warranted.